1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use

Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use

Summary

GBI Research has released its pharmaceutical research, "Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use", which provides insights into three cardiovascular therapeutic indications in in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the cardiovascular therapeutic indications, namely heart failure, myocardial infarction (MI), acute coronary syndrome (ACS). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three cardiovascular indications.

Scope

- Disease overview and treatment usage patterns
- Market size and forecast for heart failure, MI and ACS in APAC market from 2012 to 2019
- Major marketed products for the indications types covered
- In-depth pipeline analysis for heart failure, MI and ACS
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements in the cardiovascular market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the cardiovascular market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table Of Contents

Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use
Table of Contents

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
3 Therapeutic Landscape 11
3.1 Heart Failure 11
3.1.1 Symptoms 11
3.1.2 Etiology 12
3.1.3 Pathophysiology 12
3.1.4 Co-morbidities and Complications 12
3.1.5 Diagnosis 13
3.1.6 Classification 14
3.1.7 Prognosis and Disease Staging 14
3.1.8 Treatment Options 15
3.2 Myocardial Infarction 18
3.2.1 Symptoms 18
3.2.2 Etiology 18
3.2.3 Pathophysiology 18
3.2.4 Co-morbidities and Complications 19
3.2.5 Diagnosis 19
3.2.6 Classification 20
3.2.7 Treatment Options 21
3.3 Acute Coronary Syndrome 22
3.3.1 Symptoms 22
3.3.2 Etiology 22
3.3.3 Pathophysiology 23
3.3.4 Diagnosis 23
3.3.5 Treatment Options 24
4 Marketed Products 26
4.1 Heart Failure 26
4.2 Myocardial Infarction 26
4.3 Acute Coronary Syndrome 26
4.4 Key Marketed Products 26
4.4.1 Arixtra 26
4.4.2 Brilinta 28
4.4.3 Crestor 29
4.4.4 Diovan and Diovan HCT/Co-Diovan 30
4.4.5 Atacand 30
4.4.6 Lipitor 31
4.4.7 Clopidogrel bisulfate 32
4.4.8 Angiomax 32
4.4.9 Lovenox 33
4.4.10 Norvasc 34
4.4.11 Coreg 34
4.4.12 Ivabradine 36
4.4.13 Toprol-XL 36
5 Pipeline Analysis 38
5.1 Heart Failure Pipeline 38
5.1.1 Overall Pipeline 38
5.1.2 Pipeline Analysis by Molecule Type 39
5.1.3 Pipeline Analysis by Mechanism of Action 40
5.2 Myocardial Infarction Pipeline 41
5.2.1 Overall Pipeline 41
5.2.2 Pipeline Analysis by Molecule Type 42
5.2.3 Pipeline Analysis by Mechanism of Action 43
5.3 Acute Coronary Syndrome Pipeline 44
5.3.1 Overall Pipeline 44
5.3.2 Pipeline Analysis by Molecule Type 45
5.3.3 Pipeline Analysis by Mechanism of Action 46
5.4 Promising Drug Candidates in the Pipeline 47
5.4.1 LCZ-696 47
5.4.2 Darapladib (SB-480848) 48
5.4.3 Neucardin 49
5.4.4 Cangrelor 50
5.4.5 Serelaxin (Novartis AG) 50
6 Market Forecast to 2019 51
6.1 Asia-Pacific Market 51
6.1.1 Treatment Usage Patterns 51
6.1.2 Annual Cost of Therapy 51
6.1.3 Market Size 51
6.2 Australia 53
6.2.1 Treatment Usage Patterns 53
6.2.2 Annual Cost of Therapy 53
6.2.3 Market Size 53
6.3 China 55
6.3.1 Treatment Usage Patterns 55
6.3.2 Annual Cost of Therapy 55
6.3.3 Market Size 55
6.4 Japan 57
6.4.1 Treatment Usage Patterns 57
6.4.2 Annual Cost of Therapy 57
6.4.3 Market Size 57
6.5 India 59
6.5.1 Treatment Usage Patterns 59
6.5.2 Annual Cost of Therapy 59
6.5.3 Market Size 59
6.6 Drivers and Barriers for the Global Cardiovascular Diseases Market 61
6.6.1 Drivers 61
6.6.2 Barriers 62
7 Deals and Strategic Consolidations 63
7.1 Deals Analysis 63
7.2 Major Co-Development Deals 65
7.2.1 Genzyme Enters into Agreement with Osiris Therapeutics 66
7.2.2 Les Laboratoires Servier Enters into Co-development Agreement with miRagen Therapeutics 66
7.2.3 Cytokinetics Signs Strategic Agreement with Amgen 66
7.2.4 Biogen Idec Inc. Enters into Agreement with Cardiokine Inc. 66
7.2.5 Bristol-Myers Squibb Enters into Co-Development Agreement with Ambrx Inc. 67
7.2.6 Angioblast Systems Inc. Enters into Co-Development Agreement with Abbott India Limited 67
7.3 Major Licensing Deals 68
7.3.1 Cephalon Inc. Enters into Licensing Agreement with Mesoblast Limited for Regenerative Medicine 69
7.3.2 The Medicines Company Enters into Licensing Agreement with Pfizer Inc. 69
7.3.3 BioLineRx, Ltd. Enters into Licensing Agreement With Ikaria Holdings, Inc. 69
7.3.4 KAI Pharmaceuticals, Inc. Enters into Licensing Agreement with Bristol-Myers Squibb 69
7.3.5 Theravance, Inc. Enters into Licensing Agreement with Merck and Co., Inc. for Cardiovascular Therapeutic Candidates 70
7.3.6 Novartis AG Enters into License Agreement with Portola Pharmaceuticals, Inc. 71
7.3.7 Salix Pharmaceuticals, Ltd. Enters into License Agreement with Merck and Co, Inc. 71
7.3.8 Amgen Enters into Licensing Agreement with Cytokinetics 71
8 Appendix 72
8.1 All Pipeline Drugs by Phase 72
8.1.1 Preclinical 72
8.1.2 Pre-registration 76
8.1.3 Phase I 76
8.1.4 Phase II 78
8.1.5 Phase III 80
8.2 Market Forecasts to 2019 81
8.2.1 Global 81
8.2.2 Australia 82
8.2.3 China 83
8.2.4 Japan 84
8.2.5 India 85
8.3 Market Definitions 86
8.4 Abbreviations 86
8.5 Sources 88
8.6 Research Methodology 89
8.6.1 Coverage 89
8.6.2 Secondary Research 89
8.6.3 Primary Research 90
8.6.4 Therapeutic Landscape 90
8.6.5 Geographical Landscape 93
8.6.6 Pipeline Analysis 93
8.7 Expert Panel Validation 93
8.8 Contact Us 93
8.9 Disclaimer 93



List of Tables

Table 1: Cardiovascular Diseases Market, Asia-Pacific, General Symptoms of Congestive Heart Failure by Stage, 2013 11
Table 2: Cardiovascular Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 72
Table 3: Cardiovascular Market, Global, Pharmaceutical Pipeline (Pre-registration), 2013 76
Table 4: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase I), 2013 76
Table 5: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase II), 2013 78
Table 6: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase III), 2013 80
Table 7: Cardiovascular Diseases Market to 2019, Heart Failure, Asia-Pacific, Market Forecast, 2012-2019 81
Table 8: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Market Forecast, 2012-2019 81
Table 9: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Market Forecast, 2012-2019 81
Table 10: Cardiovascular Diseases Market to 2019, Heart Failure, Australia, Market Forecast, 2012-2019 82
Table 11: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Australia, Market Forecast, 2012-2019 82
Table 12: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Australia, Market Forecast, 2012-2019 82
Table 13: Cardiovascular Diseases Market to 2019, Heart Failure, China, Market Forecast, 2012-2019 83
Table 14: Cardiovascular Diseases Market to 2019, Myocardial Infarction, China, Market Forecast, 2012-2019 83
Table 15: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, China, Market Forecast, 2012-2019 83
Table 16: Cardiovascular Diseases Market to 2019, Heart Failure, Japan, Market Forecast, 2012-2019 84
Table 17: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Japan, Market Forecast, 2012-2019 84
Table 18: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Japan, Market Forecast, 2012-2019 84
Table 19: Cardiovascular Diseases Market to 2019, Heart Failure, India, Market Forecast, 2012-2019 85
Table 20: Cardiovascular Diseases Market to 2019, Myocardial Infarction, India, Market Forecast, 2012-2019 85
Table 21: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, India, Market Forecast, 2012-2019 85



List of Figures

Figure 1: Cardiovascular Diseases Market, Asia-Pacific, Heart Failure Treatment Algorithm, 2013 17
Figure 2: Cardiovascular Diseases Market, Asia-Pacific, Subtypes of Myocardial Infarction by Clinical Scenario, 2013 20
Figure 3: Cardiovascular Diseases Market, Asia-Pacific, Acute Coronary Syndrome Treatment Algorithm, 2013 25
Figure 4: Cardiovascular Diseases Market , Arixtra, Global, Annual Sales ($m), 2009-2012 27
Figure 5: Cardiovascular Diseases Market, Brilinta, Global, Annual Sales ($m), 2011-2012 28
Figure 6: Cardiovascular Diseases Market, Crestor, Global, Annual Sales ($m), 2009-2012 29
Figure 7: Cardiovascular Diseases Market to 2019, Lovenox, Global, Annual Sales ($m), 2009-2012 33
Figure 8: Cardiovascular Diseases Market, Coreg, Global, Annual Sales ($m), 2006-2012 35
Figure 9: Cardiovascular Diseases Market to 2019, Toprol-XL, Global, Annual Sales ($m), 2007-2012 37
Figure 10: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline, 2012 38
Figure 11: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline by Molecule Type, 2012 39
Figure 12: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline by Mechanism of Action, 2012 40
Figure 13: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline, 2012 41
Figure 14: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline by Molecule Type, 2012 42
Figure 15: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline by Mechanism of Action, 2012 43
Figure 16: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline, 2012 44
Figure 17: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline by Molecule Type, 2012 45
Figure 18: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline by Mechanism of Action, 2012 46
Figure 19: Cardiovascular Diseases to 2019, APAC, Market Size ($m), 2012-2019 52
Figure 20: Cardiovascular Diseases Market to 2019, Australia, Market Size ($m), 2012-2019 54
Figure 21: Cardiovascular Diseases Market to 2019, China, Market Size ($m), 2012-2019 56
Figure 22: Cardiovascular Diseases Market to 2019, Japan, Market Size ($m), 2012-2019 58
Figure 23: Cardiovascular Diseases Market to 2019, India, Market Size ($m), 2012-2019 60
Figure 24: Cardiovascular Diseases Market to 2019, Global, Deals, 2007-2013 64
Figure 25: Cardiovascular Market, Global, Co-development Deals, 2007-2013 65
Figure 26: Cardiovascular Diseases Market to 2019, Global, Licensing Deals, 2007-2013 68
Figure 27: GBI Research Market Forecasting Model 92

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.